Long-Term TRIANGLE Trial Results Compare First-Line Regimens in Mantle Cell Lymphoma

The briefing

The ASCO Post highlights The Lancet’s long-term follow-up from the phase III TRIANGLE trial across 13 European countries and Israel, involving 870 previously untreated mantle cell lymphoma patients aged 18–65 eligible for ASCT. The open-label study compares three first-line regimens, reporting durability and safety findings to inform treatment selection.